Vivace Therapeutics Inc. has synthesized transcriptional coactivator YAP1/TEAD and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer, polycystic kidney and hepatic fibrosis.

Synnovation Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities).

Fundamental Pharma GmbH has described TRPM4/NMDA interaction inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS).

Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.

Nuevolution A/S has synthesized bromodomain-containing protein 4 (Brd4, HUNK1) inhibitors reported to be useful for the treatment of cancer, hypoxia, fibrosis, autoimmune disease, inflammatory disorders and viral infections.

Shenzhen Forward Pharmaceuticals Co. Ltd. has disclosed fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.

Beigene Ltd. has identified IL-17A/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis.

St. Jude Children’s Research Hospital has described pregnane X receptor (PXR) modulators reported to be useful for the treatment of cancer.

Virginia Commonwealth University has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, myocardial infarction, arthritis, diabetes, gout, COVID-19, Alzheimer’s and Parkinson’s disease, among others.

Blueprint Medicines Corp. has identified KIT (c-KIT) (mutant) inhibitors reported to be useful for the treatment of gastrointestinal stromal tumors (GIST).